尿激酶型纤溶酶原激活物受体（uPAR）是一种糖基磷脂酰肌醇锚定的膜蛋白，已被发现在多种癌细胞中过表达，这一特性使得uPAR成为治疗癌症的一个理想靶标。目前，多种以uPAR为靶点的抗癌药物已被开发，主要包括多肽、单克隆抗体、配体靶向毒素。此外，uPAR作为靶点也已在纳米药物递送系统和光热疗法（PTT）/光动力疗法（PDT）中得到应用。因此就靶向uPAR的抗肿瘤药物的研究进展做一综述。

Urokinase-type plasminogen activator receptor (uPAR) is a glycosyl phosphatidyl inositol-anchored membrane protein which has been found to be over-expressed in a variety of cancer cells, and this property makes uPAR a promising candidate for cancer treatment. At present, a variety of anti-tumor drugs targeting uPAR have been developed, mainly including peptides, monoclonal antibodies, and ligand-targeted toxins. In addition, uPAR has also been used as a target in nano-drug delivery systems and photothermal therapy (PTT)/photodynamic therapy (PDT). Therefore, this paper reviews the research progress of anti-tumor drugs targeting uPAR.

R979.1

陕西省教育厅重点科研计划项目（21JS009）；陕西省科技厅自然科学基础研究计划项目（2022JQ-932）；西安市卫生健康委员会项目（SZY202103）